Table 1.

Risk of subsequent mortality due to ALS after cancer by cancer site and latency in whites in 16 SEER registries

Cancer site	O	1–4 years			5–9 years			≥10 years			Total
		SMR	95 % CI	O	SMR	95 % CI	O	SMR	95 % CI	O	SMR	95 % CI	PYR
All cancers (excluding nonmelanoma skin)	534	1.00	0.92–1.09	356	1.01	0.91–1.12	326	1.00	0.89–1.11	1,216	1.00	0.95–1.06	16,613,508
Tongue	8	3.17	1.36–6.24	3	1.94	0.39–5.67	3	2.20	0.44–6.42	14	2.57	1.41–4.32	80,669
Colon	52	1.03	0.77–1.34	37	1.14	0.80–1.57	32	1.02	0.70–1.44	121	1.06	0.88–1.26	1,312,300
Rectum	13	0.95	0.50–1.62	5	0.58	0.19–1.34	9	1.02	0.47–1.94	27	0.87	0.57–1.26	376,420
Bronchus and lung	25	0.95	0.62–1.41	14	1.24	0.68–2.09	5	0.59	0.19–1.19	44	0.96	0.70–1.29	558,556
Female breast	93	1.11	0.89–1.36	59	0.93	0.71–1.20	77	1.08	0.85–1.35	229	1.05	0.91–1.19	3,757,698
Uterine corpus	22	1.14	0.72–1.73	17	0.96	0.56–1.53	37	1.23	0.86–1.69	76	1.13	0.89–1.42	991,734
Prostate	150	0.90	0.76–1.06	93	0.84	0.68–1.03	46	0.77	0.57–1.03	289	0.86	0.76–0.96	2,864,323
Urinary bladder	36	0.95	0.66–1.31	28	1.10	0.73–1.59	25	1.02	0.66–1.51	89	1.01	0.81–1.25	935,406
Kidney parenchyma/renal pelvis	7	0.57	0.23–1.18	10	1.35	0.65–2.48	8	1.16	0.50–2.02	25	0.94	0.61–1.39	366,216
Melanoma of the skin	27	1.34	0.88–1.95	26	1.85	1.20–2.70	25	1.37	0.89–2.02	78	1.49	1.17–1.85	1,004,503
All leukemia	13	1.22	0.65–2.09	10	1.73	0.83–3.18	1	0.24	0–1.35	24	1.17	0.75–1.74	362,607
Non-Hodgkin’s lymphoma	16	0.83	0.48–1.35	12	1.12	0.58–1.95	11	1.28	0.64–2.30	39	1.01	0.72–1.38	592,704

O observations, SMR standardized mortality ratio, PYR person-years